Relmada Therapeutics (RLMD) Projected to Post Quarterly Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.05). On average, analysts expect Relmada Therapeutics to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Stock Down 2.7%

Shares of NASDAQ:RLMD opened at $2.20 on Tuesday. Relmada Therapeutics has a twelve month low of $0.24 and a twelve month high of $3.67. The stock’s 50 day moving average is $1.82 and its 200-day moving average is $1.02. The firm has a market capitalization of $73.02 million, a price-to-earnings ratio of -0.99 and a beta of 0.87.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Relmada Therapeutics in a research report on Friday. Wall Street Zen raised Relmada Therapeutics to a “hold” rating in a research report on Saturday, October 11th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Relmada Therapeutics has an average rating of “Reduce” and a consensus price target of $1.00.

Institutional Trading of Relmada Therapeutics

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd purchased a new position in shares of Relmada Therapeutics during the second quarter valued at approximately $28,000. Goldman Sachs Group Inc. purchased a new stake in shares of Relmada Therapeutics during the first quarter worth about $33,000. LMR Partners LLP bought a new position in Relmada Therapeutics during the second quarter valued at approximately $33,000. Jane Street Group LLC bought a new stake in shares of Relmada Therapeutics in the 2nd quarter valued at approximately $69,000. Finally, Marshall Wace LLP purchased a new stake in shares of Relmada Therapeutics in the second quarter worth approximately $93,000. Institutional investors own 45.24% of the company’s stock.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.